Dechallenge and Rechallenge Assessment

Dechallenge and rechallenge describe what happens to a suspected adverse event when a drug is stopped and, sometimes, restarted. Improvement of the event after withdrawal (positive dechallenge) and its recurrence after readministration (positive rechallenge) are among the strongest single-case criteria that a drug, rather than another cause, was responsible.

Definition

Dechallenge is the observation of an adverse event's course after the suspected drug is discontinued, and rechallenge is the observation of its course after the drug is reintroduced; a reaction that abates on dechallenge and reappears on rechallenge strengthens the inference that the drug caused it.

Scope

This entry explains the two criteria, their interpretation (positive, negative, or uninformative), the reasons a deliberate rechallenge is often impossible or unethical, and how they feed into structured causality tools. It is a methodological reference and not guidance on whether to stop or restart any medicine in an individual patient.

Core questions

• What distinguishes a positive, negative, and uninformative dechallenge or rechallenge?
• Why is a positive rechallenge considered strong evidence of drug causation?
• When is deliberate rechallenge inappropriate, and how does that limit the criterion's availability?
• How do these criteria enter structured algorithms and likelihood categories?

Key concepts

• Positive vs. negative dechallenge
• Positive vs. negative rechallenge
• Uninformative (inconclusive) challenge
• Inadvertent rechallenge
• Reversibility of the reaction
• Ethical and safety limits on deliberate rechallenge
• Confounding by concurrent treatment changes

Mechanisms

On dechallenge, an adverse event that resolves or improves when the drug is withdrawn is consistent with drug causation, provided the reaction is reversible and no other treatment changed at the same time; an event that persists despite withdrawal argues against the drug but does not exclude irreversible injury. On rechallenge, recurrence of the same event when the drug is reintroduced provides strong support for causation because it reproduces the temporal association under fresh observation. Interpretation depends on whether the reaction is expected to reverse, whether other interventions changed simultaneously, and whether the rechallenge was deliberate or inadvertent. Because deliberate rechallenge can expose the patient to renewed harm, it is frequently neither attempted nor ethical, so many assessments rely on dechallenge alone or on inadvertent rechallenge captured in the report (Karch & Lasagna 1977; Naranjo 1981).

Clinical relevance

Dechallenge and rechallenge information is among the most weighted evidence in case reports and in tools such as the Naranjo algorithm and RUCAM, so recognising how these criteria are scored supports critical appraisal of safety reports. The entry describes how this evidence is interpreted and is not a basis for individual decisions to withdraw or rechallenge a medicine.

Evidence & guidelines

Structured causality instruments assign substantial weight to dechallenge and rechallenge: the Naranjo algorithm includes explicit items for improvement on withdrawal and reappearance on readministration (Naranjo 1981), and organ-specific tools such as RUCAM for drug-induced liver injury formalise dechallenge dynamics and treat a positive rechallenge as strongly supportive (Danan & Teschke 2018). These criteria are valued precisely because they observe the drug-event relationship over time rather than relying on background plausibility alone.

History

The diagnostic value of stopping and restarting a suspected agent is long established in clinical pharmacology, and the formalisation of adverse drug reaction assessment in the 1970s made dechallenge and rechallenge explicit criteria. Karch and Lasagna incorporated them into their operational framework, and Naranjo's 1981 algorithm encoded both as scored items, cementing their role in modern causality assessment.

Debates

How much should a single positive rechallenge count?

A positive rechallenge is widely regarded as strong evidence, yet deliberate rechallenge is often unethical and inadvertent rechallenges may be confounded by other changes, so assessors must weigh its persuasive power against the limited and sometimes biased circumstances in which it is observed.

Key figures

• Fred E. Karch
• Louis Lasagna
• Cesar A. Naranjo
• Gaby Danan

Seminal works

• karch-lasagna-1977
• naranjo-1981

Frequently asked questions

What is the difference between dechallenge and rechallenge?

Dechallenge observes the adverse event after the drug is stopped; rechallenge observes it after the drug is restarted. Improvement on dechallenge and recurrence on rechallenge both support drug causation.

Why is rechallenge often not performed?

Deliberately restarting a drug that may have harmed a patient can cause the reaction to recur and is frequently unsafe or unethical, so many assessments rely on dechallenge or on rechallenges that happened inadvertently.